This article was crafted with AI assistance.

[TITLE level="1"]` shortcode.

Maximize Longevity — 6 Genes And 7 Biomarkers To Track

Introduction

Most people who want to live longer and healthier receive broadly similar advice: eat better, exercise more, sleep enough, reduce stress. That advice is not wrong. But for many people, it is not sufficient — and for some, it is actively incomplete. Two individuals can follow identical protocols and experience entirely different outcomes, because their biochemistry is not identical.

This gap between population-level guidance and individual results is exactly where biomarkers and genetics become valuable. A single overlooked marker like ApoB can reveal cardiovascular risk that a standard lipid panel misses entirely. A genetic variant in MTHFR can explain why a person does not respond to folic acid supplementation. Knowing these specifics does not guarantee a longer life, but it makes your decisions far more targeted — and far more likely to produce a meaningful result.

This article takes a more precise approach. Rather than listing longevity tips, it focuses on the most actionable data points that current research consistently connects to long-term health outcomes. For each biomarker and each gene, you will find what it reveals, how to measure or assess it, and what you can realistically do when a result is suboptimal — with or without supplements or equipment.

Two main angles are covered: first, the 7 most important biomarkers to track, with specific protocols for each suboptimal score; then, a look at 6 key genes that may shape your longevity trajectory and what to do about each one. A summary of one of the most important books on this topic and a selection of complementary approaches with meaningful human evidence round out the picture. The goal is not to overwhelm but to give you a genuinely useful foundation to act from.

7 Biomarkers to Track for a Longer, Healthier Life

Standard blood panels were designed to diagnose disease, not to optimize longevity. Most routine panels include LDL-C, total cholesterol, fasting glucose, and a handful of other markers — but leave out some of the most predictive data points available. The 7 biomarkers below represent a more precise and actionable longevity panel, built on the frameworks used by physicians like Peter Attia, Thomas Dayspring, and Allan Sniderman.

1. ApoB — The True Measure of Cardiovascular Risk

Why it matters: ApoB (apolipoprotein B) is a protein found on every atherogenic lipoprotein particle — including LDL, VLDL, and IDL. While LDL-C measures the total cholesterol content inside LDL particles, ApoB counts the number of those particles. It is the particle count, not the cholesterol content, that determines how often your arterial wall is exposed to potential injury. Research consistently shows that ApoB is a stronger predictor of cardiovascular events than LDL-C, particularly in individuals with normal LDL-C but a high number of small, dense LDL particles — a pattern that a standard lipid panel will completely miss. This discordance is far more common than most people realize.

How to measure it: A standard blood draw ordered through any clinical lab. The test is widely available and costs between $20 and $60 depending on the provider. It is not automatically included in routine panels, so you may need to request it explicitly. For longevity purposes, most clinicians following this approach target ApoB below 80 mg/dL, and below 60 mg/dL for individuals with existing cardiovascular risk factors.

If the score is suboptimal — the plan without supplements: The most powerful dietary lever is reducing refined carbohydrates and ultra-processed foods, which drive excess VLDL production and raise particle number. Replacing saturated fat with monounsaturated fat (olive oil, avocados, nuts) tends to lower ApoB more reliably than simply reducing total fat. Sustained aerobic exercise — particularly moderate-intensity cardio 4 to 5 sessions per week — improves lipoprotein metabolism over time. Reducing visceral fat has one of the most direct and measurable effects on ApoB levels.

If the score is suboptimal — the plan with supplements or equipment: Statins remain the most evidence-backed pharmacological option for lowering ApoB. If statins are poorly tolerated, PCSK9 inhibitors (injectable, prescription) are a highly effective alternative. Among supplements, berberine at 500 mg twice daily with meals has shown modest ApoB-lowering effects in several clinical trials and is a reasonable starting point. Ezetimibe (prescription, non-statin) reduces intestinal cholesterol absorption and lowers ApoB with a very favorable side effect profile. Psyllium husk (5–10 g daily with meals) reduces LDL particle concentration modestly and is safe for long-term use. Soluble fiber from oats (beta-glucan) has a similar mechanism with good evidence.

2. Lp(a) — The Genetic Risk Factor Most People Have Never Heard Of

Why it matters: Lipoprotein(a), or Lp(a), is a modified LDL particle carrying an additional protein called apolipoprotein(a). Elevated Lp(a) is an independent, causal risk factor for atherosclerosis, aortic stenosis, and thrombosis. Unlike almost every other cardiovascular marker, it is almost entirely genetically determined — diet, exercise, and weight loss have minimal impact on it. Approximately 20% of the global population carries levels above 50 mg/dL, which most guidelines consider high-risk. The majority of these individuals have never had it tested, and their standard lipid panel gives no hint that there is a problem.

How to measure it: A single blood test. Lp(a) should be measured at least once in a lifetime, ideally in early adulthood or at first cardiovascular risk assessment — particularly if a first-degree relative has a history of premature cardiovascular disease. Cost ranges from $20 to $80. The test is often not covered by insurance without documented indication.

If the score is suboptimal — the plan without supplements: Direct lifestyle modifications have very limited impact on Lp(a) levels themselves. However, aggressively managing every other cardiovascular risk factor — keeping ApoB low, controlling blood pressure, avoiding smoking, maintaining metabolic health — significantly reduces the overall risk burden that elevated Lp(a) creates. The risk is compounded, not additive, so improving everything else matters substantially.

If the score is suboptimal — the plan with supplements or equipment: No supplement reliably lowers Lp(a) in a clinically meaningful way. Niacin at high therapeutic doses (1.5–3 g/day) has shown 20–30% Lp(a) reductions in some studies but did not demonstrate improved cardiovascular outcomes in large trials, and the side effect profile is significant — requiring supervision. PCSK9 inhibitors (evolocumab, alirocumab) reduce Lp(a) by roughly 25–30% as a secondary effect and are the best currently available pharmacological option for elevated Lp(a) with concurrent elevated LDL. RNA-targeting therapies currently in advanced clinical trials (such as olpasiran and pelacarsen) are showing 70–90% Lp(a) reductions and may change this landscape significantly within the next few years. If your Lp(a) is elevated, the priority is proactive cardiovascular risk management with a knowledgeable cardiologist.

3. Fasting Insulin and HOMA-IR — The Earliest Warning Sign for Metabolic Decline

Why it matters: Fasting glucose is typically the first metabolic marker tested — and among the last to become abnormal. By the time fasting glucose is elevated, significant metabolic dysfunction has usually been present for years. Fasting insulin and HOMA-IR (a calculated index using fasting glucose and insulin together) reveal insulin resistance far earlier in its development. Insulin resistance is now recognized as a common denominator underlying type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, polycystic ovary syndrome, certain cancers, and accelerated cognitive decline. Catching it early — when it is still entirely reversible — changes the health trajectory dramatically.

How to measure it: HOMA-IR is calculated from a fasting blood draw measuring both glucose and insulin simultaneously. Cost: $30–$80 total depending on the lab. HOMA-IR below 1.0 is considered optimal; values above 2.5 indicate meaningful insulin resistance. Most standard panels skip fasting insulin entirely — it must be specifically requested.

If the score is suboptimal — the plan without supplements: Time-restricted eating (confining food intake to an 8–10 hour window) reduces insulin exposure throughout the day without requiring caloric restriction. Reducing refined carbohydrates and added sugar directly lowers per-meal insulin demand. Resistance training is particularly effective at improving insulin sensitivity by increasing glucose uptake into muscle tissue and expanding glycogen storage capacity. Post-meal walks of even 10–15 minutes significantly blunt postprandial glucose and insulin spikes. Sleep quality is frequently underestimated: a single night of poor sleep can acutely worsen insulin sensitivity by 20–30% in otherwise healthy individuals.

If the score is suboptimal — the plan with supplements or equipment: Berberine (500 mg, 2–3 times daily with meals) has demonstrated insulin-sensitizing effects comparable in magnitude to low-dose metformin in several randomized trials — it is among the best-supported metabolic supplements. Magnesium glycinate or citrate (300–400 mg daily) is commonly deficient in insulin-resistant individuals, and supplementation improves insulin sensitivity modestly. Myo-inositol (2–4 g/day) has strong evidence in PCOS-related insulin resistance and broader metabolic benefits in some populations. A continuous glucose monitor (CGM) — worn for just 2–4 weeks — is one of the most powerful available tools for understanding your personal glucose response patterns and guiding meaningful dietary changes. Metformin (prescription) is worth discussing with a physician for moderate to severe HOMA-IR elevation.

4. hs-CRP — Tracking the Slow Fire of Chronic Inflammation

Why it matters: High-sensitivity C-reactive protein (hs-CRP) is the most widely used clinical marker of systemic inflammation. Chronic low-grade inflammation — sometimes called "inflammaging" — is now understood as a central driver of biological aging itself, associated with cardiovascular disease, neurodegeneration, metabolic syndrome, and cancer. Standard CRP tests lack the sensitivity to detect the low-level, persistent inflammation that accumulates over years without causing acute symptoms. The hs-CRP test is calibrated for this purpose and is far more predictive for longevity risk stratification.

How to measure it: A standard blood test available as an add-on to basic panels. Cost: $10–$40. Optimal for longevity purposes: below 0.5 mg/L. Elevated concern begins above 1.0 mg/L; above 3.0 mg/L indicates high cardiovascular inflammatory risk. The test should not be performed during or shortly after an acute illness or injury, as CRP spikes dramatically in those contexts and would give a falsely elevated reading.

If the score is suboptimal — the plan without supplements: Visceral fat is the most potent single driver of elevated hs-CRP, and losing it consistently produces measurable reductions. An anti-inflammatory dietary pattern — emphasizing vegetables, omega-3-rich fatty fish, extra-virgin olive oil, legumes, and avoiding ultra-processed foods — has well-documented effects on hs-CRP over 8–12 weeks. Regular aerobic exercise reduces hs-CRP through multiple mechanisms. Sleep optimization is essential: chronic sleep restriction (under 6 hours nightly) raises inflammatory cytokines dose-dependently. Psychological stress management, when practiced systematically, also produces measurable anti-inflammatory effects.

If the score is suboptimal — the plan with supplements or equipment: Omega-3 fatty acids (EPA+DHA, 2–4 g/day from high-quality fish oil or algae-based supplements) are among the best-studied anti-inflammatory interventions, with multiple trials showing meaningful hs-CRP reduction. Curcumin in a bioavailable form — with piperine, or as a phytosome formulation (500–1000 mg/day) — reduces inflammatory markers in numerous trials, though effect sizes vary with formulation quality. Vitamin D supplementation (2000–4000 IU/day when baseline is below 40 ng/mL) has anti-inflammatory effects that are most pronounced when correcting deficiency. Magnesium (300–400 mg/day) has consistent if modest evidence for CRP reduction. Sauna use (4–7 sessions per week at 80°C, 15–20 minutes) has epidemiological associations with lower inflammatory markers and cardiovascular mortality.

5. Homocysteine — The Methylation Proxy

Why it matters: Homocysteine is an amino acid produced during methionine metabolism. Elevated homocysteine (above 10–12 µmol/L) is associated with cardiovascular disease, stroke, cognitive decline, and impaired DNA repair. It reflects problems in the methylation cycle — usually driven by B vitamin insufficiency, genetic variants (particularly MTHFR), or both. This is one of the most correctable biomarkers in the longevity panel and one of the most frequently overlooked. Many labs consider anything below 15 µmol/L "normal," which is far too permissive by longevity standards.

How to measure it: A standard blood test, often available as an add-on. Cost: $20–$60. For longevity optimization, target below 8 µmol/L. Request it specifically — it is not part of standard routine panels in most health systems.

If the score is suboptimal — the plan without supplements: Ensure consistent dietary intake of folate (leafy greens, lentils, asparagus), vitamin B12 (animal products, especially eggs, fish, and meat), and B6 (poultry, fish, potatoes). Reducing alcohol is important — even moderate alcohol consumption impairs folate metabolism and raises homocysteine. Regular aerobic exercise has a modest homocysteine-lowering effect in some trials. Avoiding prolonged use of medications that deplete B vitamins (notably metformin for B12, and oral contraceptives for B6 and folate) is worth discussing with a prescribing physician.

If the score is suboptimal — the plan with supplements or equipment: This is one of the most directly correctable biomarkers through targeted supplementation. Methylfolate (5-MTHF, 400–1000 mcg/day) is the active form that bypasses the MTHFR enzyme step — preferable to folic acid for most people, and especially for MTHFR carriers. Methylcobalamin (B12, 500–1000 mcg/day sublingually) is the active form most effective for methylation support. Pyridoxal-5-phosphate (P5P, active B6, 25–50 mg/day) is a required cofactor in the transsulfuration pathway. The combination of these three B vitamins has robust evidence for lowering elevated homocysteine in randomized controlled trials. TMG (trimethylglycine or betaine) at 500–1500 mg/day provides an alternative methylation route and can meaningfully reduce homocysteine when B vitamins alone are insufficient. No cycling is required for these water-soluble vitamins, but B6 above 200 mg/day carries a neuropathy risk — stay well below that threshold.

6. IGF-1 — The Growth Hormone Axis and Longevity

Why it matters: Insulin-like growth factor 1 (IGF-1) mediates many effects of growth hormone and regulates cell growth, proliferation, and metabolism. The relationship between IGF-1 and longevity is complex and follows a J-shaped curve: both very high and very low levels are associated with poor outcomes. Chronically elevated IGF-1 is linked to accelerated cellular aging, increased cancer incidence, and cardiovascular disease. Chronically low IGF-1 impairs muscle maintenance, immune function, and recovery. For longevity, the evidence consistently points to a middle-to-low-normal range as optimal — making this one of the few markers where higher is emphatically not better.

How to measure it: A blood test (serum IGF-1). Cost: $40–$100. Reference ranges are age-dependent; for longevity purposes, most researchers and clinicians working in this space prefer levels in the lower half of the age-adjusted reference range for adults over 40.

If the score is suboptimal — the plan without supplements: If IGF-1 is high: reducing animal protein intake (particularly dairy and red meat), shortening eating windows, and incorporating regular fasting periods reliably lower IGF-1 over several weeks. If IGF-1 is low: adequate protein intake (1.2–1.6 g/kg/day) combined with progressive resistance training are the primary physiological stimulants. Quality sleep is essential — the majority of growth hormone pulsing, and downstream IGF-1 production, occurs during deep sleep stages. Even one week of sleep deprivation can significantly reduce IGF-1 levels.

If the score is suboptimal — the plan with supplements or equipment: If IGF-1 is chronically low and dietary protein and resistance training have been optimized, zinc (15–30 mg/day, taken with food) supports healthy growth hormone receptor signaling. Vitamin D (when deficient) plays a role in IGF-1 production and receptor sensitivity. Regular sauna use (4–7 sessions per week at 80–100°C, 15–20 minutes) is associated with significant acute growth hormone pulses and may support IGF-1 over time. For clinically low IGF-1 due to documented growth hormone deficiency, growth hormone replacement is a medical option evaluated case-by-case. Rapamycin (prescription mTOR inhibitor) reduces IGF-1 signaling when levels are high — it is under active longevity investigation but is not standard care outside research settings.

7. HbA1c — The Long View on Blood Sugar

Why it matters: HbA1c reflects average blood glucose over the previous 2–3 months by measuring the proportion of hemoglobin that has been glycated. Unlike a single fasting glucose measurement, it shows cumulative glucose exposure — making it a far more stable and meaningful marker. Even modestly elevated HbA1c in the "prediabetic" range (5.7–6.4%) is associated with accelerated biological aging, cardiovascular risk, early kidney function decline, and impaired cognitive performance. Many longevity-focused clinicians target HbA1c below 5.3%, which is meaningfully more stringent than the standard lab reference of 5.6%.

How to measure it: A standard blood test included in many routine panels. Cost: $10–$40. Among the most accessible and affordable longevity biomarkers available. Re-test every 3–6 months when actively working to lower it; annually for maintenance.

If the score is suboptimal — the plan without supplements: Dietary approaches mirror insulin resistance management: reducing refined carbohydrates and added sugars, increasing fiber and protein per meal, and prioritizing whole foods. Resistance training significantly improves HbA1c by increasing muscle mass and glycogen storage capacity — muscle is the primary site of postprandial glucose disposal. Post-meal walks of 10–15 minutes have a disproportionately large impact on 24-hour glucose control and are one of the highest-leverage lifestyle interventions relative to effort. Consistent sleep (7–9 hours) and stress reduction both contribute meaningfully.

If the score is suboptimal — the plan with supplements or equipment: Berberine (500 mg, 2–3 times daily with meals) has multiple randomized trial data for HbA1c reduction, with effects comparable in some studies to low-dose metformin. Ceylon cinnamon (1–3 g/day with meals) modestly improves postprandial glucose metabolism in some trials. Alpha-lipoic acid (600 mg/day) improves insulin receptor sensitivity and has evidence for modest HbA1c improvement. A CGM worn for 2–4 weeks provides far more actionable personalized data than a quarterly HbA1c reading. Metformin (prescription, 500–1500 mg/day) is a widely studied and well-tolerated first-line pharmacological option for those in the prediabetic range, worth discussing with a physician.

With biomarkers giving you a clear picture of where you are today, the next layer — genetics — helps explain why those numbers look the way they do and what underlying tendencies may need lifelong attention.

The Genetic Layer: 6 Genes That May Shape Your Longevity

Understanding your biomarkers tells you where your biology stands today. Genetics adds a different kind of information: the constraints and tendencies your body started with. These are not fixed destinies — most longevity-relevant gene variants are probabilistic, not deterministic — but knowing your genotype allows you to intervene upstream, often before a biomarker even becomes abnormal. Consumer genetic testing (23andMe, AncestryDNA) provides some data; clinical panels from companies like Genomind or direct lab testing provide more.

APOE — Alzheimer's Risk and Lipid Transport

What it may affect: The APOE gene encodes a protein central to lipid transport throughout the body and brain. Three main variants exist: E2, E3 (the most common), and E4. Carrying one copy of APOE4 raises lifetime Alzheimer's disease risk approximately 3–4 times; carrying two copies raises it 8–12 times. APOE4 also impairs lipid clearance from the bloodstream, making carriers more susceptible to elevated LDL-C and Lp(a). Roughly 25% of the population carries at least one E4 allele — a substantial proportion of whom are entirely unaware of it.

If the gene may limit progress — the plan without supplements: APOE4 carriers benefit most from intensive and early cardiovascular risk reduction: maintaining ApoB below 70 mg/dL, keeping hs-CRP consistently low, and staying aerobically fit — aerobic fitness appears to reduce dementia risk more substantially in APOE4 carriers than non-carriers. A Mediterranean dietary pattern has direct evidence for cognitive benefit in this population. Prioritizing sleep quality is especially critical: the glymphatic system — responsible for amyloid clearance from the brain — is most active during deep sleep, and APOE4 impairs this clearance, making every hour of restorative sleep particularly valuable.

If the gene may limit progress — the plan with supplements or equipment: Omega-3 fatty acids (EPA+DHA, 2–4 g/day) are particularly relevant for APOE4 carriers, who show worse cognitive outcomes when omega-3 status is low. Daily or 5x/week continuously. Phosphatidylserine (100 mg, 3 times daily) has some evidence for cognitive support in high-risk populations. Quercetin (500 mg/day) and resveratrol (250–500 mg/day) activate SIRT1 and AMPK pathways that may partially compensate for APOE4-related mitochondrial dysfunction — some researchers suggest cycling resveratrol (5 days on, 2 off) to avoid blunting exercise adaptation signals. Sauna use (4–7 sessions/week) has epidemiological data linking it to reduced dementia risk, with plausible mechanisms including heat shock protein activation and improved cerebral blood flow.

MTHFR — The Methylation Gene

What it may affect: MTHFR encodes an enzyme that converts dietary folate into its active form (5-methyltetrahydrofolate, or 5-MTHF), essential for the methylation cycle. The most common variants — C677T and A1298C — reduce enzyme efficiency by 30–65% in heterozygous and homozygous carriers respectively. Impaired methylation raises homocysteine, reduces DNA repair capacity, and may affect neurotransmitter synthesis pathways involving serotonin and dopamine. These variants are extremely prevalent — C677T homozygous affects roughly 10–15% of many European and Latin American populations — making them among the most clinically significant common gene variants in the longevity context.

If the gene may limit progress — the plan without supplements: Prioritize dietary folate from leafy greens, lentils, asparagus, and avocado (not folic acid from fortified foods, which MTHFR carriers process poorly and may accumulate as unmetabolized folic acid). Ensure consistent B12 intake from dietary animal sources. Reduce alcohol, which compounds folate depletion. Measure homocysteine as the primary functional readout of methylation status — it tells you whether your current approach is working.

If the gene may limit progress — the plan with supplements or equipment: The core protocol is straightforward: methylfolate (5-MTHF, 400–1000 mcg/day) bypasses the impaired enzyme step entirely. Add methylcobalamin (B12, 500–1000 mcg/day sublingual) and pyridoxal-5-phosphate (active B6, 25–50 mg/day). TMG (trimethylglycine, 500–1000 mg/day) provides an alternative methylation route via betaine. Start with low doses and increase gradually — a small percentage of individuals with heightened sensitivity experience over-methylation symptoms (anxiety, irritability, insomnia) that resolve with dose reduction. No cycling required for these water-soluble vitamins; B6 should be kept well below 200 mg/day.

FTO — Obesity Risk and Appetite Regulation

What it may affect: The FTO gene (Fat Mass and Obesity Associated) contains variants strongly associated with increased body mass index, preferential fat mass accumulation, and appetite dysregulation. The risk allele impairs satiety signaling and appears to promote preference for energy-dense foods. Carriers do not inevitably become obese — gene-environment interaction is substantial — but they face a consistently higher challenge in maintaining healthy weight and metabolic biomarkers, particularly in environments where calorie-dense food is abundant and easily available.

If the gene may limit progress — the plan without supplements: Protein-dominant meals (targeting 30+ g per sitting) are particularly effective for FTO risk carriers, as dietary protein has the strongest and most durable satiety effect and directly counteracts the appetite dysregulation associated with the variant. Resistance training counteracts the fat-mass tendency more reliably than cardio alone. Consistent meal timing — rather than irregular or ad hoc eating patterns — reduces the unpredictable hunger cues FTO carriers frequently experience. Removing highly palatable ultra-processed foods from the immediate environment has outsized impact for this genotype.

If the gene may limit progress — the plan with supplements or equipment: GLP-1 receptor agonists (prescription, e.g., semaglutide or tirzepatide) directly address appetite dysregulation through a mechanism highly relevant to FTO-related signaling — they are among the most evidence-backed pharmacological options for this profile. Among supplements, glucomannan (1–2 g before meals with a large glass of water) is a viscous fiber that substantially increases satiety. Berberine (500 mg, 2–3x daily) has complementary metabolic benefits. A CGM used for 2–4 weeks helps FTO carriers understand precisely how different food combinations affect their glucose — and by extension, their hunger cycles.

FOXO3 — The Longevity Gene

What it may affect: FOXO3 is one of the most consistently replicated longevity-associated genes in human research. Specific variants of this gene are significantly enriched in centenarians across multiple diverse populations — including Japanese Americans in Hawaii, Italians, Germans, and Chinese cohorts — suggesting a robust and population-independent effect. FOXO3 regulates insulin and IGF-1 signaling, oxidative stress resistance, DNA damage response, cell cycle checkpoint control, and autophagy — essentially a master regulator of multiple core aging mechanisms. A landmark study by Willcox and colleagues (PNAS, 2008) was among the first to establish this association in humans (Willcox et al., PNAS 2008).

If the gene may limit progress — the plan without supplements: For individuals without the beneficial variants, the FOXO3 pathway can still be meaningfully upregulated through behavioral interventions. Caloric restriction and intermittent fasting activate FOXO3 by reducing insulin and IGF-1 signaling. Sustained aerobic exercise upregulates FOXO3 in muscle tissue. Maintaining low chronic insulin levels — through dietary choices that avoid persistent hyperinsulinemia — prevents the phosphorylation that keeps FOXO3 in its inactive, cytoplasmic form.

If the gene may limit progress — the plan with supplements or equipment: Resveratrol (250–500 mg/day) activates SIRT1, which deacetylates and activates FOXO3 — cycle 5 days on, 2 off if training regularly, to avoid blunting exercise adaptation. Quercetin (500 mg/day, continuous) has synergistic AMPK and FOXO3-activating effects. Fisetin (100–500 mg/day, or periodic higher-dose 2-day senolytic protocols every 2–3 months) acts partly through FOXO-related pathways and has senolytic evidence in human cell studies. Metformin (prescription) activates AMPK, which in turn activates FOXO3 — a key reason it is the subject of the TAME longevity trial currently underway. Rapamycin (mTOR inhibitor, prescription) activates FOXO3 indirectly and is under investigation in longevity research settings; not yet standard care.

PCSK9 — LDL Regulation and Cardiovascular Risk

What it may affect: PCSK9 encodes a protein that binds to LDL receptors in the liver and targets them for degradation. Higher PCSK9 activity means fewer LDL receptors, which means more circulating LDL and ApoB. Gain-of-function variants in PCSK9 substantially raise cardiovascular risk. Loss-of-function variants — occurring naturally in some West African and other populations — produce lifelong very low LDL-C and dramatically reduced rates of coronary artery disease, providing compelling causal evidence for the ApoB-cardiovascular disease hypothesis and forming the biological basis for the entire class of PCSK9 inhibitor drugs.

If the gene may limit progress — the plan without supplements: For gain-of-function carriers, aggressive dietary management is the starting point: reducing saturated fat and replacing it with monounsaturated fat, increasing soluble fiber from oats (beta-glucan), psyllium, and legumes, and maintaining a high-vegetable, whole-food pattern. Regular aerobic exercise improves hepatic LDL receptor activity. Monitoring ApoB (not just LDL-C) is essential to track the actual particle burden.

If the gene may limit progress — the plan with supplements or equipment: Statins (prescription) are particularly indicated for documented gain-of-function PCSK9 variants and provide substantial ApoB reduction. PCSK9 inhibitors (evolocumab/Repatha, alirocumab/Praluent — self-administered monthly or bimonthly injections) directly neutralize the PCSK9 protein and reduce LDL-C by 50–65% on top of statin therapy. Inclisiran (Leqvio — biannual injection) uses RNA interference to silence PCSK9 gene expression with equivalent efficacy and exceptional adherence advantages. Berberine (500 mg, 2–3x daily) has shown modest PCSK9-lowering effects in several trials and may serve as a useful supplement-level adjunct.

CETP — HDL Function and Reverse Cholesterol Transport

What it may affect: CETP (Cholesteryl Ester Transfer Protein) regulates the transfer of cholesterol esters from HDL to atherogenic lipoproteins. Certain CETP variants that reduce enzyme activity are associated with elevated HDL-C levels and are enriched in centenarian studies — suggesting that lower CETP activity and higher functional HDL may contribute to exceptional longevity. However, pharmaceutical CETP inhibitors that dramatically raised HDL-C did not consistently improve cardiovascular outcomes in large trials, making clear that HDL-C quantity alone is not the relevant variable — HDL function and the quality of reverse cholesterol transport matter far more than the number.

If the gene may limit progress — the plan without supplements: Rather than chasing HDL-C numbers, focus on HDL functional quality. Aerobic exercise is the single most effective intervention for improving reverse cholesterol transport capacity, regardless of CETP genotype. Avoiding smoking and trans fats protects HDL from oxidation and functional impairment. A Mediterranean dietary pattern consistently supports healthy HDL metabolism and particle functionality.

If the gene may limit progress — the plan with supplements or equipment: Niacin raises HDL-C substantially but failed to improve clinical cardiovascular outcomes in the large AIM-HIGH and HPS2-THRIVE trials — it is not recommended for HDL elevation as a standalone goal. Omega-3 fatty acids (EPA+DHA, 2–4 g/day) modestly improve HDL particle size and function. Regular vigorous aerobic exercise (30+ minutes at moderate to vigorous intensity, 4–5 times/week) remains the most evidence-backed and clinically meaningful intervention for improving HDL function.

With both biomarkers and genetic tendencies mapped, the table below consolidates key information for quick reference before moving on to practical implementation strategies.

Summary Table: Genes and Biomarkers at a Glance

Outlive by Peter Attia — 10 Ideas That May Change How You Think About Aging

Outlive: The Science and Art of Longevity by Peter Attia (2023) stands as one of the most influential books on longevity to emerge in recent years. Its power lies in the way it integrates research across multiple disciplines — cardiovascular medicine, oncology, metabolism, neuroscience, and behavioral science — into a coherent framework for decision-making. It directly challenges the reactive, symptom-focused approach of conventional medicine in favor of what Attia calls "Medicine 3.0": proactive, personalized, probability-based. Ten of its most impactful ideas are summarized below.

1. The Four Horsemen of Chronic Disease

Attia identifies the four diseases responsible for the vast majority of deaths in the developed world: cardiovascular disease, cancer, metabolic dysfunction (type 2 diabetes and related conditions), and neurodegenerative disease. The key insight is that they share common upstream drivers — chronically elevated insulin, systemic inflammation, elevated ApoB, and oxidative stress. Addressing root causes rather than managing late-stage symptoms is the only strategy with real leverage. All four are influenced by the same biomarkers and genes covered in this article.

2. ApoB Is the Number That Matters Most for Cardiovascular Risk

Attia argues that LDL-C is an inadequate proxy for cardiovascular risk and that ApoB should become the standard measurement. He explains particle number versus cholesterol content with clarity: it is the number of atherogenic particles traversing the arterial wall daily that determines the rate of plaque accumulation, not the cholesterol they carry. He advocates for early and aggressive ApoB management — starting in one's 30s or 40s — rather than waiting for detectable atherosclerosis.

3. Atherosclerosis Begins Decades Before Symptoms

The book makes the uncomfortable but well-supported argument that significant atherosclerosis often begins in early adulthood. The window for meaningful prevention closes earlier than most people assume. This is why Attia advocates for coronary artery calcium (CAC) scoring — a low-radiation CT scan — as an objective structural measure of existing plaque burden, ideally combined with ApoB and Lp(a) testing to create a complete cardiovascular risk picture.

4. Insulin Resistance Is the Engine of Metabolic Disease

Attia dedicates substantial attention to insulin resistance as the central metabolic dysfunction that underlies most chronic disease, and explains why fasting glucose is a terrible screening tool for detecting it. He strongly advocates for fasting insulin, HOMA-IR, and the use of continuous glucose monitors to understand individual glucose dynamics — tools that mainstream medicine rarely deploys for prevention purposes.

5. Zone 2 Training Is the Most Underused Longevity Tool

One of Attia's most actionable recommendations is consistent Zone 2 aerobic training — sustained effort at roughly 60–70% of maximum heart rate, enough to hold a conversation but no more. This intensity specifically trains mitochondrial efficiency, improves fat oxidation, reduces insulin resistance, and improves lipid metabolism. He recommends a minimum of 3 hours per week of Zone 2 work, ideally 4+, as a non-negotiable longevity investment.

6. VO2 Max Is the Single Strongest Predictor of All-Cause Mortality

Attia cites the remarkable data showing that VO2 max — maximum aerobic capacity — is among the most powerful predictors of all-cause mortality available. Moving from the bottom quartile to the second quartile of VO2 max reduces mortality risk more than quitting smoking. He recommends 1–2 Zone 5 (maximum effort) intervals per week as a targeted VO2 max training strategy in addition to Zone 2 work.

7. Protein and Muscle Are Critical Priorities as You Age

Attia challenges the conventional view that high protein intake is problematic and argues instead that most people eat far too little — particularly older adults experiencing sarcopenia. He recommends 1.6 g of protein per kilogram of body weight per day as a longevity-oriented target, emphasizing that maintaining muscle mass protects against metabolic disease, falls, cognitive decline, and loss of independence in later decades.

8. Sleep Is Not Optional — It Is Infrastructure

The book frames sleep not as a lifestyle preference but as biological infrastructure without which every other longevity intervention underperforms. Poor sleep raises cortisol and inflammatory cytokines, worsens insulin sensitivity, impairs amyloid clearance from the brain, and disrupts hormonal regulation. Attia recommends treating sleep quality with the same rigor applied to nutrition and exercise — tracking it, protecting it, and identifying and addressing specific disruptions like sleep apnea.

9. Emotional Health Is Not Separate From Physical Longevity

One of the book's most unexpected threads is its frank exploration of psychological health as a determinant of longevity. Attia argues that unresolved emotional dysfunction — chronic stress, relational conflict, trauma — creates biological damage through sustained cortisol and inflammatory pathways that no supplement or training protocol can fully overcome. Structured interventions including therapy, mindfulness, and behavioral work are presented as genuine longevity medicine.

10. The Goal Is Not Just Living Longer — It Is the Centenarian Decathlon

Attia introduces the concept of the "Centenarian Decathlon" — defining the specific physical tasks you want to be capable of at 90 or 100, and working backward from those goals to determine what physical capacities need to be cultivated today. This reframes longevity from a passive aspiration into an active, goal-directed training project. It is a framework for turning abstract health data into concrete, personally meaningful action.

The complementary modalities in the next section offer additional tools that, while less central than biomarker testing and genetic assessment, have genuine clinical evidence behind them and may meaningfully support your overall longevity strategy.

Complementary Approaches Worth Knowing

Mindfulness Meditation and MBSR

Mindfulness-Based Stress Reduction (MBSR) is an 8-week structured program developed by Jon Kabat-Zinn that combines body scan meditation, sitting meditation, and gentle yoga to systematically reduce stress reactivity. Its relevance to longevity biomarkers is well-documented: chronic psychological stress raises cortisol, which elevates blood glucose, hs-CRP, and homocysteine, and impairs sleep quality — four of the seven biomarkers covered in this article. Reducing stress reactivity through mindfulness practice addresses these effects through a single upstream intervention.

Multiple randomized controlled trials have demonstrated measurable reductions in hs-CRP and inflammatory cytokines following MBSR participation. A meta-analysis published in Psychoneuroendocrinology found consistent reductions in cortisol and inflammatory biomarkers following mindfulness-based interventions in both healthy and clinical populations. Additional research has documented positive effects on HbA1c in type 2 diabetic patients following structured mindfulness programs, likely mediated through reduced stress-induced cortisol and improved self-regulatory behavior around food and sleep.

Practically, MBSR is accessible through certified programs, digital platforms (Insight Timer, Headspace clinical programs), and direct instruction. The formal program runs 8 weeks with 2.5-hour weekly sessions and 45 minutes of daily home practice. For those unable to commit to the full program, consistent daily practice of 15–20 minutes of focused breath meditation has shown measurable biomarker effects in trials of 8–12 weeks duration. The entry point is modest: a free guided session on any major meditation app, used daily for 30 days, provides a reasonable way to assess individual response before committing to a structured program.

Breathing-Based Therapies

Structured breathing practices — including diaphragmatic breathing, slow-paced breathing, and coherent breathing (at approximately 5–6 breaths per minute) — directly influence the autonomic nervous system by increasing parasympathetic tone and reducing sympathetic activation. This shift has measurable downstream effects on heart rate variability (HRV), blood pressure, cortisol output, and inflammatory markers. For longevity purposes, chronically elevated sympathetic tone is associated with worsened insulin sensitivity, elevated hs-CRP, and impaired sleep quality — all of which structured breathing can partially address.

A randomized controlled trial published in Hypertension demonstrated that 4 weeks of twice-daily slow breathing exercises (15 minutes per session at 6 breaths per minute) produced clinically significant reductions in systolic and diastolic blood pressure — comparable to low-dose antihypertensive medication in some participants. Separately, studies on HRV biofeedback breathing have shown improvements in cortisol regulation and subjective stress in multiple populations. High HRV is itself a marker correlated with metabolic health, lower hs-CRP, and better cardiovascular outcomes.

Practically, coherent breathing at 5–6 breaths per minute (5 seconds inhale, 5 seconds exhale) practiced for 10–20 minutes daily is the most studied and accessible protocol. Apps like Othership, Breethe, or a simple metronome provide pacing. Daily practice is recommended; effects on HRV and blood pressure are typically measurable within 4–8 weeks of consistent use. The technique has no meaningful side effects and requires no equipment, making it one of the highest-leverage low-cost interventions in this space. Morning practice before food appears to produce the most consistent HRV improvements in available data.

Microbiome-Directed Therapies

The gut microbiome — the community of trillions of microorganisms inhabiting the intestinal tract — has emerged as a significant modulator of metabolic health, systemic inflammation, and even cognitive function. Specific microbial community compositions are associated with better insulin sensitivity, lower hs-CRP, reduced homocysteine production, and improved lipid metabolism. Conversely, microbiome disruption (dysbiosis) drives inflammation and metabolic impairment through multiple mechanisms including lipopolysaccharide (LPS) translocation, altered short-chain fatty acid production, and disrupted bile acid metabolism.

Human clinical evidence for microbiome-directed interventions is strongest for dietary fiber and fermented food consumption. A landmark 2021 randomized controlled trial from Stanford (Cell, Wastyk et al.) found that a high-fermented food diet — including yogurt, kefir, kimchi, and kombucha — significantly increased microbiome diversity and reduced 19 inflammatory proteins, including IL-6 and IL-12p70, in healthy adults over 10 weeks. This effect on inflammatory markers was superior to a high-fiber diet alone in this study. Probiotic supplementation with specific well-studied strains (Lactobacillus acidophilus, Bifidobacterium longum) has also shown modest reductions in fasting glucose and insulin resistance in several randomized trials.

Practically, the intervention with the strongest evidence is dietary: adding 1–2 daily servings of fermented food (plain yogurt with live cultures, kefir, sauerkraut, kimchi, or kombucha with minimal added sugar) combined with consistent prebiotic fiber intake (onions, garlic, leeks, asparagus, bananas, oats). A high-quality probiotic supplement with documented strains and viable colony counts (10–50 billion CFU/day) is a reasonable adjunct, though strain selection matters — not all probiotics are equivalent. This is one area where personalized approaches (stool microbiome testing through companies like Viome or Genova) may offer useful guidance on individual microbial gaps. Evidence is still developing, particularly around precision microbiome interventions, but the foundational dietary approach is low-risk, low-cost, and broadly supported.

Conclusion

The most important shift this article encourages is from reactive to proactive — from waiting for symptoms to arrive before taking action, to building a clear, data-informed picture of where you stand and what is most likely to move the needle for you specifically. A handful of well-chosen biomarkers and an awareness of your key genetic tendencies can do more for long-term decision-making than years of following generic health advice.

The next smart step is concrete: request an ApoB, fasting insulin, homocysteine, and hs-CRP test at your next blood draw — they are affordable and available almost everywhere. If you have access to genetic testing, look at your APOE, MTHFR, and FOXO3 status as a starting point. Pick one underperforming biomarker, apply the protocol for it consistently over 90 days, then re-measure. Longevity is built in compounding iterations — small, informed decisions made repeatedly over time. Start with the data, then act on it.